Expression of SMAD proteins, TGF-beta/activin signaling mediators, in human thyroid tissues.

OBJECTIVE To investigate the expression of SMAD proteins in human thyroid tissues since the inactivation of TGF-beta/activin signaling components is reported in several types of cancer. Phosphorylated SMAD 2 and SMAD3 (pSMAD2/3) associated with the SMAD4 induce the signal transduction generated by TGF-beta and activin, while SMAD7 inhibits this intracellular signaling. Although TGF-beta and activin exert antiproliferative roles in thyroid follicular cells, thyroid tumors express high levels of these proteins. MATERIALS AND METHODS The protein expression of SMADs was evaluated in multinodular goiter, follicular adenoma, papillary and follicular carcinomas by immunohistochemistry. RESULTS The expression of pSMAD2/3, SMAD4 and SMAD7 was observed in both benign and malignant thyroid tumors. Although pSMAD2/3, SMAD4 and SMAD7 exhibited high cytoplasmic staining in carcinomas, the nuclear staining of pSMAD2/3 was not different between benign and malignant lesions. CONCLUSIONS The finding of SMADs expression in thyroid cells and the presence of pSMAD2/3 and SMAD4 proteins in the nucleus of tumor cells indicates propagation of TGF-beta/activin signaling. However, the high expression of the inhibitory SMAD7, mostly in malignant tumors, could contribute to the attenuation of the SMADs antiproliferative signaling in thyroid carcinomas.

[1]  R. DeLellis.  Pathology and genetics of tumours of endocrine organs , 2004 .

[2]  R. Lloyd,et al.  Localization of Inhibins and Activins in Normal Endocrine Cells and Endocrine Tumors of the Gut and Pancreas: an Immunohistochemical and In Situ Hybridization Study , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[3]  Anita B. Roberts,et al.  Peptide Growth Factors and Their Receptors I , 1990, Springer Study Edition.

[4]  H. Röher,et al.  Activin A and Activin Receptors in the Human Thyroid: A Link to the Female Predominance of Goiter? , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[5]  J. R. Thompson.  Function And Growth , 2009 .

[6]  A. Mariani,et al.  Overexpression of the TGF-beta antagonist Smad7 in endometrial cancer. , 2005, Gynecologic oncology.

[7]  R. Beauchamp,et al.  Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. , 2005, Experimental cell research.

[8]  M. Pisarev,et al.  Role of transforming growth factor beta in the regulation of thyroid function and growth. , 2009, Thyroid : official journal of the American Thyroid Association.

[9]  R. Mariani-Costantini,et al.  A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours , 2005, Oncogene.

[10]  R. Hruban,et al.  ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Derynck,et al.  TGF-beta receptor signaling. , 1997, Biochimica et biophysica acta.

[12]  E. Kimura,et al.  Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. , 2002, The Journal of clinical endocrinology and metabolism.

[13]  J. Massagué,et al.  TGFbeta signaling in growth control, cancer, and heritable disorders. , 2000, Cell.

[14]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.

[15]  J. Massagué,et al.  Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer , 2003, Nature Reviews Cancer.

[16]  D Falb,et al.  The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. , 1997, Cell.

[17]  L. Gold.  The role for transforming growth factor-beta (TGF-beta) in human cancer. , 1999, Critical reviews in oncogenesis.

[18]  Jennifer Lee,et al.  Smad7 but not Smad6 cooperates with oncogenic ras to cause malignant conversion in a mouse model for squamous cell carcinoma. , 2003, Cancer research.

[19]  R. Herrmann,et al.  SMAD7 is a prognostic marker in patients with colorectal cancer , 2003, International journal of cancer.

[20]  K. Yamato,et al.  Smad7 Is an Activin-inducible Inhibitor of Activin-induced Growth Arrest and Apoptosis in Mouse B Cells* , 1998, The Journal of Biological Chemistry.

[21]  E. Kimura,et al.  Transforming growth factor-beta1 and activin A generate antiproliferative signaling in thyroid cancer cells. , 2006, The Journal of endocrinology.

[22]  K. Miyazono,et al.  Signaling inputs converge on nuclear effectors in TGF-β signaling , 2000 .

[23]  W. Vale,et al.  Roles of pathway-specific and inhibitory Smads in activin receptor signaling. , 1999, Molecular endocrinology.

[24]  G. Risbridger,et al.  Activins and inhibins in endocrine and other tumors. , 2001, Endocrine reviews.

[25]  E. J. Lee,et al.  Activin A mediates growth inhibition and cell cycle arrest through Smads in human breast cancer cells. , 2005, Cancer research.

[26]  J. Massagué,et al.  Mechanisms of TGF-beta signaling from cell membrane to the nucleus. , 2003, Cell.

[27]  E. Kimura,et al.  Acquired and naturally occurring resistance of thyroid follicular cells to the growth inhibitory action of transforming growth factor-β1 (TGF-β1) , 1996 .

[28]  S. Pangas,et al.  Activin Signal Transduction Pathways , 2000, Trends in Endocrinology & Metabolism.

[29]  J. Hershman,et al.  Transforming growth factor-beta blocks protein kinase-A-mediated iodide transport and protein kinase-C-mediated DNA synthesis in FRTL-5 rat thyroid cells. , 1992, Endocrinology.

[30]  Xiao-Fan Wang,et al.  Activin induces hepatocyte cell growth arrest through induction of the cyclin-dependent kinase inhibitor p15INK4B and Sp1. , 2004, Cellular signalling.

[31]  K. Miyazono,et al.  Signaling inputs converge on nuclear effectors in TGF-beta signaling. , 2000, Trends in biochemical sciences.

[32]  P. Kopp,et al.  Expression of Transforming Growth Factor β1, β2, and β3 in Multinodular Goiters and Differentiated Thyroid Carcinomas: A Comparative Study , 1999 .

[33]  C. Heldin,et al.  Transforming Growth Factor β1 Induces Nuclear Export of Inhibitory Smad7* , 1998, The Journal of Biological Chemistry.

[34]  S. Ying,et al.  Regulation of Cell Proliferation, Apoptosis, and Carcinogenesis by Activin 1 , 2002, Experimental biology and medicine.

[35]  J. Wrana,et al.  The MAD-Related Protein Smad7 Associates with the TGFβ Receptor and Functions as an Antagonist of TGFβ Signaling , 1997, Cell.

[36]  J. Wrana,et al.  TGF-beta and the Smad signal transduction pathway. , 2002, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[37]  J. Ricarte-Filho,et al.  [TGFbeta, activin and SMAD signalling in thyroid cancer]. , 2007, Arquivos brasileiros de endocrinologia e metabologia.

[38]  E. Kimura,et al.  Activin betaB expression in rat experimental goiter and human thyroid tumors. , 2003, Thyroid : official journal of the American Thyroid Association.

[39]  J. Massagué,et al.  Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus , 2003, Cell.

[40]  M. Goumans,et al.  Regulation of cell proliferation by Smad proteins , 2002, Journal of cellular physiology.

[41]  C. Heldin,et al.  Smad regulation in TGF-beta signal transduction. , 2001, Journal of cell science.

[42]  J. Dumont,et al.  General inhibition by transforming growth factor β1 of thyrotropin and cAMP responses in human thyroid cells in primary culture , 1993, Molecular and Cellular Endocrinology.

[43]  E. Piek,et al.  Expression of transforming growth factor-beta1, activin A, and their receptors in thyroid follicle cells: negative regulation of thyrocyte growth and function. , 1999, Endocrinology.

[44]  A. Mariani,et al.  Overexpression of the TGF-β antagonist Smad7 in endometrial cancer , 2005 .

[45]  M. Sporn,et al.  The Transforming Growth Factor-βs , 1991 .

[46]  C. Heldin,et al.  Induction of inhibitory Smad6 and Smad7 mRNA by TGF-beta family members. , 1998, Biochemical and biophysical research communications.